



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 95/23790

(51) International Patent Classification 6:
C07D 233/64, 235/14, A61K 31/415

A1

(11) International Publication Number:

(43) International Publication Date: 8 September 1995 (08.09.95)

(21) International Application Number: PCT/US95/02606
(22) International Filing Date: 3 March 1995 (03.03.95)

(30) Priority Data: 3 March 1994 (03.03.94)
9404046.6

GB

(71) Applicant (for all designated States except US): SMITHKLINE
BEECHAM CORPORATION [US/US]; Corporate Intellec-
tual Property, UW2220, 709 Swedeland Road, P.O. Box
1539, King of Prussia, PA 19406-0939 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): FRAZEE, James, Simpson
[US/US]; 5 Buffalo Run, Sewell, NJ 08080 (US). GLEA-
SON, John, Gerald [CA/US]; 8 Heron Hill Drive, Downing-
town, PA 19335 (US). METCALF, Brian, Walter [US/US];
520 Woodland Drive, Radnor, PA 19087 (US).

(74) Agents: DINNER, Dara, L. et al.; SmithKline Beecham
Corporation, Corporate Intellectual Property, UW2220, 709
Swedeland Road, P.O. Box 1539, King of Prussia, PA
19406-0939 (US).

(81) Designated States: JP, US, European patent (AT, BE, CH, DE,
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Published
With international search report.

(54) Title: CYTOKINE INHIBITING IMIDAZOLE SUBSTITUTED HYDROXAMIC ACID DERIVATIVES

(57) Abstract

The present invention relates to a series of novel imidazole substituted hydroxamic acid derivatives, and compositions useful thereof as inhibitors of matrix degrading metalloproteinases, in particular collagenase.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

**"CYTOKINE INHIBITING IMIDAZOLE SUBSTITUTED HYDROXAMIC ACID
DERIVATIVES"**

FIELD OF THE INVENTION

This invention relates to novel compounds for both pharmaceutical and veterinary treatment of matrix-degrading metalloproteinase related disease states.

10

BACKGROUND OF THE INVENTION

Many different metalloproteinase enzymes are involved in connective tissue degradation or breakdown, such as collagenase, stromelysin and gelatinase. Inhibitors of matrix degrading metalloproteinases (MMP's) are known to be useful in the treatment or prophylaxis of conditions involving such tissue degradation. Such diseases include rheumatoid arthritis, osteoarthritis, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumor invasion or metastasis, in the promotion of wound healing, osteoporosis, rheumatoid arthritis, periodontitis, gingivitis, and corneal ulceration, gastric ulceration.

20

A number of hydroxamic acid derivatives have been suggested as being useful as collagenase inhibitors, or for promoting tumor regression, such as those in the following patents and patent applications: US 4,599,361; EP 236872; WO 90/05716; WO 91/02716; WO 90/05719; WO 93/20047; EPO 0 498 665 A1; and WO 93/21942.

25

These compounds, however, have generally poor pharmacokinetic properties and or poor water solubility. Therefor a need still exists to identify novel compounds which overcome these deficiencies.

30 SUMMARY OF THE INVENTION

The present invention relates to a series of novel imidazole substituted hydroxamic acid derivatives, and compositions useful thereof as inhibitors of matrix-degrading metalloproteinase. By inhibiting the action of metalloproteinases the compounds of Formula (I) may be used in the treatment of disease states mediated thereby.

35


This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier.

SUBSTITUTE SHEET (RULE 26)

This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I).

Compounds of Formula (I) have the following structure:

5



wherein

10 R₁ is hydrogen, hydroxy, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkenyl, phenyl, optionally substituted phenyl C₁₋₆ alkyl-, R₇-S(O)_nC₁₋₆-alkyl-; n is 0 or an integer having a value of 1 or 2;

15 R7 is C1-6 alkyl, phenyl, phenyl C1-6 alkyl, heterocyclic, heterocyclic C1-6 alkyl, heteroaryl, heteroaryl C1-6 alkyl, C1-6 alkyl carbonyl, or phenacyl, all of which may be optionally substituted one to four time independently from C1-6 alkyl, C1-6 alkoxy, hydroxy, thio C1-6alkyl, amino, halogen, CF₃ or nitro;

R₂ is hydrogen, C₁-6alkyl, C₁-6 alkenyl, phenyl C₁-6 alkyl, cycloalkyl C₁-6 alkyl, or cycloalkenyl C₁-6 alkyl;

R₃ is hydrogen or methyl;

20 R4 is hydrogen, C1-6 alkyl, cyclopropyl, an amino acid residue, optionally substituted phenyl, optionally substituted phenyl C1-6 alkyl-, optionally substituted -C1-6-alkyl-oxy C1-6alkyl, optionally substituted -C1-6 alkyl oxyC1-6 alkyl phenyl, or an optionally substituted -C1-6 alkyl oxy phenyl;

wherein the phenyl or benzyl moiety is independently substituted one to four times by halogen, C1-6 alkyl, C1-6 alkoxy, hydroxy, thiol, C1-6alkylthio-,
-NR₁₂R₁₃, -NHR^a, -NO₂, -C(O)₂R₁₄, -C(O)₂NR₁₂R₁₃, cyanoamino,
R₁₄C(O)-O-, C1-6 alkyl OH, C1-6alkyl-C(O)₂R₁₄, C1-6alkyl-oxy-C1-6alkyl,
C(O)C1-6 alkylNR₁₂R₁₃, or C1-6alkyl-(O)₂C-R₁₄ ;

R^a is hydrogen, C₁₋₆ alkyl, or the side chain of an amino acid,

30 R₁₄ is hydrogen, C₁-6 alkyl, C₃-7 cycloalkyl, C₃-7 cycloalkyl C₁-6 alkyl, arylC₁-6alkyl, heteroarylC₁-6alkyl, or heterocyclic C₁-6 alkyl;

R₅ is hydrogen or C₁₋₆alkyl;


- R₆ and R₇ are independently hydrogen, halogen, CF₃, C₁₋₆ alkyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroarylC₁₋₆alkyl, heterocyclic, heterocyclic C₁₋₆ alkyl, (CHR₈)m' OH, (CHR₈)m C(O)₂R₁₀, (CHR₈)m C(OH)(R₉)₂, (CR₈R₉)-OH, C(O)R₁₁, C(O)NR₁₂R₁₃, C(O)₂R₁₀, or NO₂; or R₆ and R₇ can together form a fused C 2-4 alkylene, aryl or heteroaryl moiety;
- m is 0 or an integer having a value of 1 or 2;
- m' is an integer having a value of 1, 2, or 3;
- R₈ and R₉ are independently hydrogen, C₁₋₄ alkyl or phenyl;
- R₁₀ is hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₆ alkyl, C₅₋₇ cycloalkenyl, arylC₁₋₆alkyl, heteroarylC₁₋₆alkyl, heterocyclic, heterocyclic C₁₋₆ alkyl all of which may be optionally substituted by halogen, hydroxyl, -C₁₋₆alkoxy, -thioC₁₋₆ alkyl, or CF₃;
- R₁₁ is hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₆ alkyl, C₅₋₇ cycloalkenyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroarylC₁₋₆alkyl, heterocyclic, heterocyclic C₁₋₆ alkyl all of which may be optionally substituted by halogen, hydroxyl, -C₁₋₆ alkoxy, -thioC₁₋₆ alkyl, or CF₃;
- R₁₂ and R₁₃ are independently hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₆ alkyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroaryl C₁₋₆alkyl, heterocyclic, heterocyclic C₁₋₆ alkyl or R₁₂ and R₁₃ may together with the nitrogen to which they are attached form a 5 to 7 membered ring which may additionally contain another heteroatom selected from O/N/ or S;
- or a pharmaceutically acceptable salt thereof.

25 DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds, specifically racemic mixtures and stereoisomers thereof are included within the scope of the present invention.

30

Compounds of Formula (I) have the preferred chiral structure shown below and, illustrated herein with R₂ as isobutyl.



Additionally, compounds in which the chiral centre adjacent to the substituent R₄ has the S stereochemistry and/or the chiral centre adjacent to the substituent R₂ which has an R stereochemistry are preferred.

Suitably, R₁ is hydrogen, hydroxy, or phenyl, benzyl, or R₇-S(O)_n C₁₋₆ alkyl- wherein the C₁₋₆ alkyl is preferably methylene. R₇ is preferably phenyl and n is 0.

Suitably, R₂ is C₁₋₆ alkyl, more preferably isobutyl.

10 Suitably, R₃ is hydrogen or methyl, preferably hydrogen.

Suitably, R₄ is hydrogen, C₁₋₆ alkyl, cyclopropyl, an amino acid residue, optionally substituted phenyl, optionally substituted phenyl C₁₋₆ alkyl-, optionally substituted -C₁₋₆-alkyl-oxy C₁₋₆alkyl, optionally substituted -C₁₋₆ alkyl oxyC₁₋₆ alkyl phenyl, or an optionally substituted -C₁₋₆ alkyl oxy phenyl; wherein the phenyl or benzyl moiety is independently substituted one to four times by halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, thiol, C₁₋₆alkylthio-, -NR₁₂R₁₃, -NHR^a, -NO₂, -C(O)₂R₁₄, -C(O)₂NR₁₂R₁₃, cyanoamino, R₁₄C(O)-O-, C₁₋₆ alkyl OH, C₁₋₆alkyl-C(O)₂R₁₄, C₁₋₆alkyl-oxy-C₁₋₆alkyl, C(O)C₁₋₆ alkylNR₁₂R₁₃, or C₁₋₆alkyl-(O)₂C-R₁₄.

20 Suitably, R₆ and R₇ are independently hydrogen, bromine, chlorine, CF₃, C₁₋₆ alkyl, phenyl, (CHR₈)_m' OH, (CHR₈)_m C(O)₂R₁₀, (CHR₈)_m C(OH)(R₉)₂, (CR₈R₉)-OH, C(O)R₁₁, C(O)NR₁₂R₁₃, C(O)₂R₁₀, or NO₂; or R₆ and R₇ can together form a fused C 2-4 alkylene, aryl or heteroaryl moiety. Preferably the fused ring forms an (i.e., aryl) ring to result in a benzoimidazole moiety.

Preferably, when R₁₀ is hydrogen, or C₁₋₆ alkyl, preferably the alkyl is methyl or isopropyl.

Suitably, R₁₁ is hydrogen, C₁₋₆ alkyl, or phenyl, preferably the alkyl is methyl or isopropyl.

When either R₆ or R₇ is (CHR₈)_m C(O)₂R₁₀ than m is preferably 0 or 2.

When either R₆ or R₇ is (CHR₈)_m OH than R₈ is preferably hydrogen, methyl, isopropyl, or phenyl.

- Preferably, in a preferred grouping, R₁ is hydrogen or hydroxy; R₂ is C₁-6 alkyl, more preferably isobutyl, R₃ is hydrogen; R₄ is hydrogen, methyl, t-butyl, ethyl, propyl, isobutyl, cyclopropyl or benzyl, preferably C₁-6 alkyl, more preferably isopropyl; R₆ and R₇ are hydrogen, C₁-6 alkyl, C₃-6 cycloalkyl, phenyl, benzyl, CF₃,
 5 bromine, C(O)₂CH₃, C(H)O, CH₂OH, CH(OH)CH₃, CH(OH)isopropyl, CH(OH)phenyl, NO₂, C(O)NH₂, (CH₂)₂C(O)CH₃, or both of R₆ and R₇ are methyl, dibromo or together form a fused aryl ring with the imidazole.

- In a preferred embodiment the compounds of Formula (I) are those wherein
- 10 R₁ is hydrogen, or hydroxy;
 R₂ is C₁-6alkyl;
 R₃ is hydrogen;
 R₄ is hydrogen, C₁-6 alkyl, cyclopropyl, an amino acid residue, optionally substituted phenyl, optionally substituted phenyl C₁-6 alkyl-, optionally substituted
 15 -C₁-6-alkyl-oxy C₁-6alkyl, optionally substituted -C₁-6 alkyl oxyC₁-6 alkyl phenyl, an optionally substituted -C₁-6 alkyl oxy phenyl, or phenyl-C₁-6 alkyl-oxy C₁-6 alkyl;
 wherein the phenyl or benzyl moiety is independently substituted one to four times by halogen, C₁-6 alkyl, C₁-6 alkoxy, hydroxy, thiol, C₁-6alkylthio-,
 20 -NR₁₂R₁₃, -NHR^a, -NO₂, -C(O)₂R₁₄, -C(O)₂NR₁₂R₁₃, cyanoamino, R₁₄C(O)-O-, C₁-6 alkyl OH, C₁-6alkyl-C(O)₂R₁₄, C₁-6alkyl-oxy-C₁-6alkyl, C(O)C₁-6 alkylNR₁₂R₁₃, or C₁-6alkyl-(O)₂C-R₁₄ ;
 R₅ is hydrogen or methyl, C₁-6alkyl;
 R₆ and R₇ are independently hydrogen, bromine, chlorine, CF₃, C₁-6 alkyl, phenyl,
 25 (CHR₈)_{m'} OH, (CHR₈)_m C(O)₂R₁₀, (CHR₈)_m C(OH)(R₉)₂, (CR₈R₉)-OH, C(O)R₁₁, C(O)NR₁₂R₁₃, C(O)₂R₁₀, or NO₂; or R₆ and R₇ can together form a fused C 2-4 alkylene, aryl or heteroaryl moiety;
 m is an integer having a value of 1, 2, or 3;
 m' is 0 or an integer having a value of 1 or 2;
 30 R₈ and R₉ are independently hydrogen, C₁-4 alkyl, or phenyl;
 R₁₀ is hydrogen, or C₁-6 alkyl;
 R₁₁ is hydrogen, C₁-6 alkyl, or phenyl;
 R₁₂ and R₁₃ are independently hydrogen, C₁-6 alkyl, C₃-7 cycloalkyl, C₃-7 cycloalkyl C₁-6 alkyl, aryl, arylC₁-6alkyl, heteroaryl, heteroarylC₁-6alkyl, heterocyclic,
 35 heterocyclic C₁-6 alkyl or R₁₂ and R₁₃ may together with the nitrogen to which they are attached form a 5 to 7 membered ring which may additionally contain another heteroatom selected from O/N/ or S;
 or a pharmaceutically acceptable salt thereof.

Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent Y₁ in R₃ comprises a carboxy group. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.


Another aspect of the present invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound according to Formula (I).

The following terms, as used herein, refer to:

- "halo" - all halogens, that is chloro, fluoro, bromo and iodo;
- "alkyl" - both straight and branched chain radicals of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, and the like;
- The term "cycloalkyl" is used herein to mean cyclic radicals, preferably of 3 to 7 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
- The term "cycloalkenyl" is used herein to mean cyclic radicals, preferably of 5 to 7 carbons, which contains an unsaturated bond, including but not limited to cyclopentenyl, cyclohexenyl, and the like.
- The term "alkenyl" is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like.
- "aryl" - phenyl and naphthyl;
- "heteroaryl" (on its own or in any combination, such as "heteroaryloxy") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited to, pyrrole, thiophene, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole;

- "heterocyclic" (on its own or in any combination, such as "heterocyclalkyl")
 - a saturated or wholly or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, imidazolidine or pyrazolidine;
- 5 • The term "alkyl" or "heteroarylalkyl" or "heterocyclalkyl" is used herein to mean C₁-6 alkyl as defined above unless otherwise indicated.
- 10 • The term "amino acid residue" is used herein to mean a characteristic side chain attached to the -CH(NH₂)COOH moiety in the following R or S amino acids, glycine, phenyl glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid and aspartic acid.

- Compounds of Formula (I) are imidazole derivatives which may be readily prepared using procedures well known to those of skill in the art such as may be found in US 4,599,361; EP 236872; WO 90/05716; WO 91/02716; WO 90/05719; WO 93/20047; EPO 0 498 665 A1; and WO 93/21942 whose disclosures are hereby incorporated by reference, or may be prepared by analogous methods to those indicated herein below.

Scheme I

5

a) (1S)-1-amino-1-isopropyl-1-(imidazo-2-yl)methane, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate ("BOP" reagent), Et₃N, CH₂Cl₂; b) CF₃COOH; c) H₂NOCH₂Ph·HCl, "BOP" reagent, Et₃N, CH₂Cl₂; d) H₂, Pd/C, EtOH.


10

While the instant scheme, and scheme 2 to 4 as well are shown with a particular compound according to formula (I), here (in scheme 1) R₁ is hydrogen, R₂ is iso-butyl, R₃ is hydrogen, R₄ is isopropyl, R₅, R₆ and R₇ are hydrogen, the methods noted herein may be extrapolated to include all compounds of Formula (I) accordingly.

Monoesters of a dicarboxylic acid such as 1-Scheme-1 may be prepared according to procedures found in European Pat App. 0 498 665-A1, in particular see Example 1C, page 11 thereof. 1-Scheme-1 is coupled with a suitable amine (a), in this case a substituted aminomethyl imidazole which is available from any α-amino acid as in Scheme 3. The coupling is carried out using any standard coupling agent used in peptide synthesis, in this case "BOP" reagent to give 2-Scheme-1, in an organic solvent, such as but not limited to halogenated hydrocarbons, tetrahydrofuran, ethyl acetate, toluene, benzene, acetone, ethers, acetonitrile and DMF. The ester group in 2-Scheme-1 is deprotected using standard reagents, in this case trifluoroacetic acid as its own

20

- solvent of TFA in chloroform or TFA in methylene chloride. The carboxylic acid 3-Scheme-1 is coupled with a suitably protected hydroxylamine, in this case O-benzylhydroxylamine, using "BOP" reagent as the coupling agent in solvents such as water, aqueous hydrochloric acid, acetic acid, ethyl acetate, the various alcohols, such as ethanol, methanol or isopropanol. The protecting group on the hydroxamic acid 4-Scheme-1 is removed using standard conditions, in this case catalytic hydrogenation over a palladium catalyst, and gave the final product 5-Scheme-1.

Scheme 2

10

- a) 2 LiN(*i*-propyl)₂, *i*-butylbromide; b) (1) NaOH (2) Me₂C(OMe)₂, p-TSA; c) (1) pentafluorophenol, WSDI (2) substituted aminomethyl imidazole, DMF; d) HCl, H₂O, ethylene glycol; e) BnONH₂·HCl, Et₃N, WSDI; f) H₂, Pd/C

SUBSTITUTE SHEET (RULE 26)

The diester of malic acid, commercially available, 1-Scheme-2 can be alkylated according to the procedure of Seebach *et al.*, *Helv. Chim. Acta*, 1980, 63, 197. In this case the dianion of the diester is alkylated with *i*-butyl bromide to give 2-Scheme-2, wherein R₂ is isobutyl and R₁ is hydroxyl, under reaction conditions wherein the

5 solvents such as THF, ether, or dimethoxy ethane are suitably used, and a primary or secondary bromide derivative of R₂ may be used. The esters can be cleaved under standard hydrolytic conditions, in this case with aqueous NaOH, (or NaOH in aq. alcohols or aq. THF) and the α -hydroxy carboxylic acid can be protected as the


10 acetonide, in this case by reaction of the hydroxy acid with dimethoxypropane under acid catalysis, in this case using *p*-toluenesulfonic acid. 3-Scheme-2 is first coupled with pentafluorophenol using a standard coupling agent, in this case a water soluble diimide (WSDI), specifically 1-ethyl-3-dimethylaminopropyl-carbodiimide methiodide in organic solvents such as the halogenated hydrocarbons, tetrahydrofuran, ethyl

15 acetate, toluene, benzene, acetone, ethers, acetonitrile and DMF; and the resultant active ester is coupled with a suitably substituted aminomethyl imidazole obtained from the procedure of 4-Scheme 4 in solvents such as DMF or chlorinated hydrocarbons. In this instance, R₃ is hydrogen, R₄ is isopropyl, R₆ and R₇ are hydrogen, and R₅ as a hydrogen is suitably protected, this compound being derived from valine. The

20 acetonide protecting group in 4-Scheme-2 can be removed under acidic conditions, in this case with aqueous HCl in ethylene glycol or any suitable alcohol. As noted in scheme 4 compounds wherein R₃ and/or R₅ is methyl can suitably be prepared. The free carboxylic acid in 5-Scheme-2 can be coupled under standard conditions with a suitably protected hydroxylamine, in this case O-benzyl-hydroxylamine, to give the protected hydroxamic acid 6-Scheme-2. Simultaneous deprotection of the hydroxamic

25 acid and the imidazole can be accomplished using conditions appropriate to the protecting groups, in this case catalytic hydrogenation over a palladium catalyst to give the final product 7-Scheme-2.

Scheme 3




- a) PhCH₂OCOCl, NaOH, aqueous Me₂CO; b) (1) pentafluorophenol, WSDI (2) HN(OMe)Me·HCl, Et₃N, DMF; c) LiAlH₄, -55°C; d) NH₃, glyoxal trimer, MeOH; e) H₂, Pd/C.

Any α-amino acid, including phenylglycine (which produces the final product of formula (I) wherein R₄ is phenyl), but in this case *tert*-leucine is illustrated for R₄ as a *t*-butyl group (*tert*-leucine is available from Aldrich Chemical Co.) which amino acid can have the nitrogen protected as a carbamate, in this case a carbobenzyloxy group, using standard conditions, such as in aq. THF, or alternatively this can be done under anhydrous condition such as triethylamine as a base and chlorinated solvents, to give 2-Scheme-3. Alternatively, amino acid derivatives of interest can be prepared in accordance with the procedures illustrated in WO93/02057, in particular, Example 1(a) whose disclosure is hereby incorporated by reference. The carboxyl group of 2-Scheme-3 is activated by formation of an active ester, in this case the pentafluorophenyl ester, the coupling between the carboxylic acid and the phenol being carried out with any water soluble diimide, in solvents such as halogenated hydrocarbons, tetrahydrofuran, ethyl acetate, toluene, benzene, acetone, ethers, acetonitrile and DMF, in this case the WSDI is 1-cyclohexyl-3-(2-morpholinoethyl)-carbodiimide metho-p-toluene-sulfonate. The active ester is coupled with N,O-dimethylhydroxylamine to give

SUBSTITUTE SHEET (RULE 26)

the amide 3-Scheme-3. The amide is reduced to the aldehyde, in this case using LiAlH_4 at reduced temperatures, in this case -55° , in solvents such as THF, ether, or dimethoxy ethane, to give the aldehyde of 4-Scheme-3. Condensation of the aldehyde with glyoxal and ammonia in any alcoholic solvent, gives the imidazole 5-Scheme-3, and the protecting group is removed using conditions appropriate for the particular protecting group, in this case catalytic hydrogenation over a palladium catalyst to give the substituted aminomethyl imidazole, 6-Scheme-3, used in scheme 1.

Appropriately substituted intermediates of 6-Scheme-3, for use in the present invention may be produced in accordance with the procedures found in WO 93/02057, supra, as follows:



R4	R5	R6	R7	Exam. #
isopropyl	Hydrogen	Hydrogen	Hydrogen	1(b)
isopropyl	Hydrogen	Hydrogen	$(\text{CH}_2)_2\text{C}(\text{O})_2\text{CH}_3$	83(b)
isopropyl	Hydrogen	Hydrogen	$\text{C}(\text{O})\text{NH}_2$	84(d)
isopropyl	Hydrogen	methyl	methyl	9(b)
isopropyl	Hydrogen	Hydrogen	phenyl	18(c)
isopropyl	Hydrogen	R6 & R7	forms fused aryl ring	4(b)
isopropyl	Hydrogen	Hydrogen	bromine	21(b)
isopropyl	Hydrogen	bromine	Bromine	22(a)
isopropyl	Hydrogen	Hydrogen	methyl	23(a)
isopropyl	Hydrogen	Hydrogen	CF_3	24(a)
isopropyl	Hydrogen	Hydrogen	$\text{C}(\text{O})_2\text{CH}_3$	26(c)
isopropyl	Hydrogen	Hydrogen	CH_2OH	30(a)
isopropyl	Hydrogen	Hydrogen	$\text{CH}(\text{O})$	27(b)
isopropyl	Hydrogen	Hydrogen	$\text{CH}(\text{OH})\text{CH}(\text{CH}_3)_2$	28(b)
isopropyl	Hydrogen	Hydrogen	$\text{CH}(\text{OH})\text{phenyl}$	29(b)
isopropyl	Hydrogen	Hydrogen	$\text{CH}(\text{OH})\text{CH}_3$	27(d)
methyl *	Hydrogen	Hydrogen	Hydrogen	6(a)
Hydrogen*	Hydrogen	Hydrogen	Hydrogen	5(a)

SUBSTITUTE SHEET (RULE 26)

R4	R5	R6	R7	Exam. #
CH ₂ -phenyl	Hydrogen	Hydrogen	Hydrogen	7(a)
ethyl	Hydrogen	Hydrogen	Hydrogen	19(b)
propyl	Hydrogen	Hydrogen	Hydrogen	20(b)
isobutyl*	Hydrogen	Hydrogen	Hydrogen	36(a)
cyclopropyl	Hydrogen	Hydrogen	Hydrogen	61(d)
isopropyl ^a	methyl	Hydrogen	Hydrogen	11(a)
isopropyl ^b	Hydrogen	Hydrogen	Hydrogen	25(b)

* is a protected site with a carbobenzyloxy moiety

^a is a protected carbobenzyloxy amino group


^b R₃ is methyl, i.e. the amino is group is NHCH₃

5

These intermediates can serve as precursors to other usefully substituted intermediates, such as where R₇ is C(O)NH₂ could also be made thru the intermediate C(O)₂Me with appropriately substituted NR₁₂R₁₃ moieties to yield the R₇ group - C(O)NR₁₂R₁₃.

Scheme 4

10



a) (1) di-*t*-butylpyrocarbonate, MeOH (2) NaOH, aqueous MeOH; b) benzyl chloromethyl ether, Et₃N, MeCN; c) (1) CF₃COOH (2) K₂CO₃.

15 A substituted aminomethyl imidazole, such as available from the procedures outlined in Scheme 3 herein, in this case (1*S*)-1-amino-1-isopropyl-1-(imidazo-2-yl)methane, 1-

SUBSTITUTE SHEET (RULE 26)

Scheme-4, can have the amino group protected, in this case as the t-butoxycarbonyl group, by reaction with a suitable derivatizing agent, in this case di-t-butyl-pyrocabonate in chlorinated solvents, or alcohols. The NH of the imidazole in compound 2-Scheme-4 can be blocked by alkylation, in this case alkylation is carried out under basic conditions with benzyl chloromethyl ether, and alternative solvents such as DMF or acetone, to give the doubly protected compound 3-Scheme-4. The protecting group on the primary amine is selectively removed, in this case with trifluoroacetic acid (neat or in chlorinated solvents), and the resulting trifluoroacetate salt of the amine is neutralized with a base to give the product 4-Scheme-4.

Alternatively, prior to selectively deprotecting the side chain nitrogen, the hydrogen may be removed and replaced with a methyl group (for R₃) with NaH and MeI and the reaction scheme proceeds accordingly, or (for R₅ other than hydrogen) using the intermediate of 2-Scheme-4 and methyl iodide instead of benzylchloromethyl ether, and working up accordingly will produce suitably substituted compounds. Yet another method for R₃ as other than hydrogen, the intermediate of 5-Scheme-3 may be used as intermediates to make other R₅ alkyl groups. Alkylation of the compound 5-Scheme-3 would first alkylate on the imidazole ring, and the resulting compound would then be used as an intermediate for alkylation, by standard means of the side chain nitrogen so that both R₃ and R₅ would be appropriately substituted.

Suitable protecting groups for use herein are well known in the art and described in many references, for instance, Protecting Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New York, 1981.

Pharmaceutically acid addition salts of compounds of formula (I) may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid in the presence of a suitable solvent.

The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

Synthetic Examples

EXAMPLE 1

N-Hydroxy-3-N'-(1'-isopropyl-1'-imidazol-2-yl)methylaminocarbonyl-5-methyl hexanamide

Preparation of (3R, 1'S)-N-Hydroxy-3-(N'-(1'-isopropyl-1'-imidazol-2-yl)methylaminocarbonyl)-5-methyl hexanamide (wherein R₁=H, R₄= i-propyl)

SUBSTITUTE SHEET (RULE 26)

a) (3R, 1'S)-*t*-butyl-3-(N'-(1'-isopropyl-1'-imidazol-2-yl) methylaminocarbonyl)-5-methyl hexanoate

A solution of (3R)-*t*-butyl-3-*i*-butyl succinate (193mg, 0.84mmole), (1S)-1-(imidazol-2-yl)-2-methylpropylamine (117mg, 0.84mmole), Et₃N (170mg, 1.68mmole) and benzotriazolo-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (372mg, 0.84mmole) in CH₂Cl₂ (10ml) was stirred for 18hr. The reaction was diluted with Et₂O (100ml), and washed with H₂O and aq Na₂CO₃. The organic extracts were dried (K₂CO₃), and the solvent removed. The residue was recrystallized from a mixture of CH₂Cl₂ and hexane to afford the title compound (160mg, 54%). ¹H NMR (400MHz, CDCl₃) δ 6.95 (s, 2H), 4.68 (t, 1H), 2.72 (m, 1H), 2.42 (m, 1H).

b) (3R, 1'S)-3-(N'-(1'-isopropyl-1'-imidazol-2-yl) methylaminocarbonyl)-5-methyl hexanoic acid, trifluoroacetate salt

A solution of the compound of Example 1(a) (160mg, 0.46mmole) in trifluoroacetic acid (5 ml) was stirred at 23° for 20h. The solvent was thoroughly evaporated, and the residue vacuum dried to afford the title compound (220mg, 100%). ¹H NMR (400MHz, CDCl₃) δ 8.78 (d, 1H), 7.29 (s, 2H), 4.90 (t, 1H), 2.90 (m, 1H).

c) (3R, 1'S)-N-benzyloxy-3-(N'-(1'-isopropyl-1'-imidazol-2-yl) methylaminocarbonyl)-5-methyl hexanamide

A solution of the compound of Example 1(b) (218mg, 0.53mmole), O-benzylhydroxylamine hydrochloride (85mg, 0.53mmole), Et₃N (214mg, 2.12mmole) and benzotriazolo-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (234mg, 0.53mmole) in CH₂Cl₂ (50ml) was stirred for 18h. The solvent was removed, and the residue taken up in EtOAc (100ml). The EtOAc was washed with H₂O, aq Na₂CO₃, dried (K₂CO₃), and the solvent evaporated. The residue was triturated with hot Me₂CO, cooled and filtered, and afforded the title compound (92mg, 44%). ¹H NMR (400MHz, CDCl₃/DMSO-D₆) δ 7.36 (m, 5H), 6.89 (s, 2H), 4.88 (t, 1H), 4.72 (d of d, 2H).

d) (3R, 1'S)-N-hydroxy-3-(N'-(1'-isopropyl-1'-imidazol-2-yl) methylaminocarbonyl)-5-methyl hexanamide

To a solution of the compound of Example 1(c) (42mg, .1mmole) in EtOH (5ml) was added 10% Pd/C (50mg), and the mixture was hydrogenated at 1 atmosphere H₂ for 4h. The catalyst was filtered, and the solvent evaporated. The residue was recrystallized from a mixture of MeOH and MeCN and afforded the title compound (18mg, 55%). (400MHz, DMSO-D₆) δ 7.90 (d, 1H), 6.80 (s, 1H), 4.74 (t, 1H), 2.74

(m, 1H), 2.30 (d of d, 1H), 2.12 (d of d, 1H), 2.04 (m, 1H), 1.42 (m, 1H), 1.34 (m, 1H), 1.06 (m, 1H), .78 (m, 12H).

5

Example 2

Preparation of (2S, 3R, 1'S)-N-2-Dihydroxy-3-[(1'-isopropyl-1'-imidazol-2-yl)methylaminocarbonyl]-5-methyl hexanamide (wherein R₁= OH, R₄= i-propyl)

a) (1S)-1-*t*-butoxycarbonylamino-1-isopropyl-1-(imidazol-2-yl)methane

10 A solution of (1S)-1-(imidazol-2-yl)-2-methylpropylamine (330mg, 2.37mmole) and di-*t*-butylpyrocarbonate (1.04g, 4.75mmole) in MeOH (5ml) was stirred for 48h. The reaction was diluted with MeOH (5ml), treated with 2.5N NaOH (2ml), and stirred for .5h. The reaction was diluted with H₂O (20ml), extracted with Et₂O, the extracts were washed with H₂O, dried (MgSO₄), and the solvent evaporated to afford the title
15 compound (462mg, 82%).

b) (1S)-1-*t*-butoxycarbonylamino-1-isopropyl-1-(1-benzyloxymethylimidazol-2-yl)methane

A mixture of the compound from Example 2(a) (442mg, 1.85mmole), benzyl
20 chloromethyl ether (318mg, 2.03mmole), and Et₃N (205mg, 2.03mmole) in MeCN (5ml) was heated at 70° for 18h. The solvent was evaporated, the residue taken up in H₂O, and extracted with Et₂O. The extracts were washed with H₂O, dried (MgSO₄), and the solvent evaporated. The residue was purified by flash chromatography (silica gel, 1% methanol/chloroform) and yielded the title compound (590mg, 89%). ¹H NMR
25 (400MHz, CDCl₃) δ 7.00 (s, 1H), 6.92 (s, 1H), 4.64 (t, 1H), 2.24 (m, 1H).

c) (1S)-1-(1-benzyloxymethylimidazol-2-yl)-2-methylpropylamine

A solution of the compound from Example 2(b) (590mg, 1.64mmole) in a
mixture of CDCl₃ (5ml) and TFA (2ml) was stirred at 23° for 4h. The solvents were
30 evaporated, and the residue was taken up in H₂O, basified, and extracted with Et₂O. The extracts were dried (MgSO₄), and the solvent evaporated to yield the title compound as an oil (380mg, 89%). ¹H NMR (400MHz, CDCl₃) δ 6.98 (s, 1H), 6.90 (s, 1H), 3.74 (d, 1H), 2.12 (m, 1H).

35 d) 2-(S)-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-(R)-yl)-4-methylpentanoic acid pentafluorophenyl ester

A solution of 2-(S)-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-(R)-yl)-4-methylpentanoic acid (1.1g, 4.78mmole), pentafluorophenol (970mg, 5.27mmole), and

1-dimethylaminopropyl-3-ethyl carbodiimide methiodide (1.42g, 4.78mmole) in CH_2Cl_2 (25ml) was stirred at 23° for 24h. The reaction was washed with H_2O , 5% aqueous K_2CO_3 , H_2O , dried (K_2CO_3), and the solvent evaporated, to yield the title compound (1.39g, 74%).

5

e) 2-(S)-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-(R)-yl)-4-methylpentanoic acid, N-[2-methyl-1-(S)-(1-benzyloxymethylimidazol-2-yl)] propylamide

A solution of the compound from Example 2(d) (1.0g, 2.53mmole), and the compound from Example 2(c) (654mg, 2.53mmole) in DMF (3ml) was stirred for 24h. The reaction was diluted with H_2O (10ml), basified (K_2CO_3), and extracted with Et_2O . The extracts were washed with H_2O , aqueous K_2CO_3 , dried (K_2CO_3), and the solvent evaporated. The residue was purified by flash chromatography (silica gel, 1% methanol/chloroform) and yielded the titled product (620mg, 52%). ^1H NMR (400MHz, CDCl_3) δ 7.00 (s, 1H), 6.91 (s, 1H), 4.96 (t, 1H), 1.54 (s, 3H), 1.50 (s, 3H).

15

f) (2S, 3R, 1'S)-2-hydroxy-3-[1'-isopropyl-1'-(1-benzyloxymethylimidazol-2-yl)methylaminocarbonyl]-5-methyl hexanoic acid

A solution of the compound in Example 2(e) (420mg, 0.89mmole) in a mixture of ethylene glycol (2ml), THF (2ml), H_2O (1ml), and 3N HCl (1ml), was stirred at 60° for 1h. The reaction was cooled to 23° and treated with a solution of LiOH (200mg) in H_2O (5ml), and stirred for 30 min. The solution was poured into a pH 5 buffer (50ml), and extracted with EtOAc. The extracts were washed once with H_2O , dried (MgSO_4), and the solvent evaporated to yield the title product (364mg, 95%). ^1H NMR (400MHz, CDCl_3) δ 7.18 (s, 1H), 6.96 (s, 1H), 4.92 (t, 1H), 4.54 (s, 2H), 4.20 (d, 1H).

25

g) (2S, 3R, 1'S)-N-benzyloxy-2-hydroxy-3-[1'-isopropyl-1'-(1-benzyloxymethylimidazol-2-yl)methylaminocarbonyl]-5-methyl hexanamide

The compound of Example 1(f) can be reacted with O-benzylhydroxylamine hydrochloride in the presence of Et_3N and benzotriazolo-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate in CH_2Cl_2 in a manner analogous to that of Example 1(c) to give the titled compound.

30

h) (2S, 3R, 1'S)-N,2-dihydroxy-3-[1'-isopropyl-1'-(imidazol-2-yl)methylaminocarbonyl]-5-methyl hexanamide

35

The compound of Example 1(g) can be deprotected by hydrogenating a solution of the compound in MeOH over a 10% Pd/C catalyst in an analogous manner to that of Example 1(d), to give the titled compound.

Example 3

Preparation of (2S, 3R, 1'S)-N-2-Dihydroxy-3-[(1'-*t*-butyl-1'-imidazol-2-yl)methylaminocarbonyl]-5-methyl hexanamide (wherein R₁= oh, R₄= *t*-butyl)

5 a) N-carbobenzyloxy-*t*-leucine

A solution of *tert*-leucine (16.7g, .13mole) in a mixture of H₂O (100ml) and 2.5N NaOH (51ml) was cooled to 0° and stirred rapidly. Solutions of benzyloxychloroformate (21.7ml, .15mole) in Me₂CO (40ml) and 2.5N NaOH (62ml) were added portionwise and alternately, at such a rate that the temperature of the reaction did not exceed 5°. After the additions, the reaction was stirred at 0° for 2h. The reaction was diluted with H₂O (200ml), and washed 3 times with Et₂O. The aqueous phase was acidified to pH 1, and extracted with CH₂Cl₂. The extracts were washed with H₂O, dried (MgSO₄), and the solvent evaporated to yield the title compound (28g, 82%). ¹H NMR (400MHz, CDCl₃) δ 7.38 (m, 5H), 5.45 (d, 1H), 5.12 (d of d, 2H), 4.22 (d, 1H), 1.00 (s, 9H).

b) N-carbobenzyloxy-*t*-leucine, pentafluorophenyl ester

A solution of the compound from Example 3(a) (1.7g, 6.4mmole), pentafluorophenol (1.2g, 6.52mmole), and 1-(2-morpholinoethyl)-3-cyclohexyl carbodiimide metho-*p*-toluene sulfonate (2.71g, 6.4mmole) in CH₂Cl₂ (50ml) was stirred at 23° for 3 days. The reaction was washed once with H₂O, and twice with aqueous K₂CO₃, dried (K₂CO₃), and the solvent removed, and yielded the title compound (2.02g, 73%). ¹H NMR (400MHz, CDCl₃) δ 5.39 (d, 1H), 5.16 (s, 2H), 4.50 (d, 1H), 1.10 (s, 9H).

c) N-methoxy-N-methyl carbobenzyloxy-*t*-leucineamide

A solution of the compound from Example 3(b) (14.82g, .034mole) and N,O-dimethylhydroxylamine hydrochloride (9.9g, 0.1mole) in DMF (200ml) was treated with Et₃N (14.25ml, 0.1mole) and stirred at 23° for 7 days. The reaction was diluted with H₂O (300ml), and extracted three times with Et₂O. The extracts were washed with H₂O, dried (K₂CO₃), and the solvent removed. Purification was accomplished by flash chromatography (silica gel, 30% EtOAc/hexane, and afforded the title product (6.2g, 59%). ¹H NMR (400MHz, CDCl₃) δ 5.10 (d of d, 2H), 4.70 (d, 1H), 3.80 (s, 3H), 3.22 (s, 3H), .98 (s, 9H).

d) carbobenzyloxy-*t*-leucinal

A solution of the compound from Example 3(c) (910mg, 2.96mmole) in THF (10ml) was cooled to -50° and treated dropwise with a 1N solution of LAH in THF

(3ml). After 1h, EtOAc (2ml) was added, and the cooling bath removed. As the reaction warmed to 23°, H₂O (.12ml), 2.5N NaOH (.18ml), and H₂O (.3ml) was added, stirring continued 30 min, and the solids filtered. The filtrate was evaporated, and afforded the title compound (630mg, 85%). ¹H NMR (400MHz, CDCl₃) δ 9.78 (s, 1H), 5.08 (s, 2H), 4.24 (d, 1H), 1.02 (s, 9H).

e) (1S)-N-carbobenzyloxy-1-(imidazol-2-yl)-2,2-dimethylpropyl amine

A solution of the compound of Example 3(d) (630mg, 2.53mmole) and glyoxal trimer dihydrate (312mg, 1.27mmole) in MeOH (4ml) containing NH₃ (200mg) was stirred at 23° for 24h. The reaction was diluted with H₂O (10ml), and extracted with EtOAc. The extracts were washed with H₂O, dried (MgSO₄), and the solvents evaporated. The residue was purified by flash chromatography (silica gel, 3% MeOH/CHCl₃) to afford the title compound (380mg, 52%). ¹H NMR (400MHz, CDCl₃) δ 6.90 (s, 2H), 5.10 (d, 1H), 5.00 (d, 1H), 4.68 (d, 1H).

f) 1-(imidazol-2-yl)-2,2-dimethylpropyl amine

A solution of the compound from Example 3(e) (380mg, 1.32mmole) in MeOH (10ml) was treated with 10%Pc/C (100mg) and hydrogenated under 1 atmosphere H₂ pressure for 48h. The catalyst was filtered, and the filtrate evaporated to afford the title compound (200mg, 100%).

g) 2-(S)-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-(R)-yl)-4-methylpentanoic acid, N-[2,2-dimethyl-1-(S)-(imidazol-2-yl)] propylamide

A solution of 2-(S)-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-(R)-yl)-4-methylpentanoic acid (346mg, 1.5mmole), hydroxybenzotriazole (300mg), 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate (635mg, 1.5mmole), and the compound from Example 3(f) (230mg, 1.5mmole) in CH₂Cl₂ (10ml) was stirred at 23° for 48h. The reaction was washed with aqueous Na₂CO₃, H₂O, dried (MgSO₄), and the solvent evaporated. The residue was purified by flash chromatography (silica gel, 3% MeOH/CHCl₃), and afforded the titled product (160mg, 28%). ¹H NMR (400MHz, CDCl₃) δ 6.98 (s, 2H), 5.20 (d, 1H), 4.50 (d, 1H), 2.88 (m, 1H), 1.50 (s, 3H), 1.42 (s, 3H), 1.00 (s, 9H).

h) (2S, 3R, 1'S)-2-hydroxy-3-[2',2'-dimethyl-1'-(imidazol-2-yl)propylaminocarbonyl]-5-methyl hexanoic acid

The compound of Example 3(g) can be reacted with HCl in a mixture of H₂O and ethylene glycol in a manner analagous to that of Example 2(f) to give the titled compound.

SUBSTITUTE SHEET (RULE 26)

i) (2S, 3R, 1'S)-N-benzyloxy-2-hydroxy-3-[2',2'-dimethyl-1'-(imidazol-2-yl)propylaminocarbonyl]-5-methyl hexanamide

The compound of Example 3(h) can be reacted with O-benzylhydroxylamine hydrochloride in the presence of Et₃N and benzotriazolo-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate in CH₂Cl₂ in a manner analogous to that of Example 1(c) to give the titled compound.

j) (2S, 3R, 1'S)-N,2-dihydroxy-3-[2',2'-dimethyl-1'-(imidazol-2-yl)propylaminocarbonyl]-5-methyl hexanamide

The compound of Example 3(i) can be deprotected by hydrogenating a solution of the compound in MeOH over a 10% Pd/C catalyst in an analogous manner to that of Example 1(d), to afford the titled compound.

In an analogous manner to that of Example 1 or by the general synthetic methods indicated herein the following compounds may be prepared:

Example 4. N-hydroxy-3-N'-(1'-*t*-butyl-1'-imidazol-2-yl)methylaminocarbonyl-5-methyl hexanamide

METHODS OF TREATMENT

The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by a matrix-degrading metalloproteinases.

Compounds of formula (I) are capable of inhibiting metalloproteinases involved in tissue degradation, such as collagenase, stromelysin, gelatinase and collagenase (IV). The role of these metalloproteinases is well known in the art and management of these metalloproteinases would be useful to treat a wide variety of disease states and conditions thereof. Most notably, diseases involving tissue degradation which includes arthropathy, such as rheumatoid arthritis, osteoporosis, inflammatory disease, dermatological diseases, bone reabsorption disease, inhibition of angiogenesis, regression of tumors and therefore in treatment of cancers caused thereby, and corneal ulceration. Many patents have published or issued to these various diseases and while not inclusive, US Patents 4,996,358; US 4,599,361; US 5,240,958; WO 91/02716; EPO 498 665 A1; WO 90/05716; WO 90/05719; and WO 93/21942 are hereby incorporated

by reference in their entirety. Similarly incorporated by reference herein is *Arthritis and Rheumatism*, 20, pg. 1231-1239 (1977) which provides evidence implicating collagenase as a key enzyme in the breakdown of articular cartilage and bone in rheumatoid arthritis. The inhibition of these metalloproteinases is of benefit in controlling, reducing and
5 alleviating many of these disease states.

Accordingly, the present invention provides a method of treating a matrix-degrading metalloproteinase mediated disease which comprises administering an effective matrix-degrading inhibiting amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In particular, the present invention is to a
10 method of treating a collagenase mediated disease state or where collagenolytic activity is important.

In particular, compounds of formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy of any disease state in a human, or other mammal, which is exacerbated by or caused by excessive or unregulated collagenolytic
15 activity by such mammal's cell.

In order to use a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a
20 compound of formula (I) and a pharmaceutically acceptable carrier or diluent.

Compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of formula (I) may be
25 administered in conventional dosage forms prepared by combining a compound of formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as
30 appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the
35 recipient thereof.

The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid

carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.

5 A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg. to about 1g. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

10 Compounds of formula (I) may be administered topically, that is by non-systemic administration. This includes the application of a compound of formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, 15 intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, 20 from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally 25 containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

30 Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin 35 such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a

polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

5 Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C. for half an hour.
10 Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

15 Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of formula (I)
20 may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.

For all methods of use disclosed herein for the compounds of formula (I), total daily dosage for oral administration will be from about 250mg to about 5000mg. A
25 suitable daily dosage will be from about 0.1mg/kg to about 300 mg/kg of total body weight, preferably from about 1 to 100 mg/kg.

The daily parenteral, in particular intra-articularly into the affected joint, will be from about .5mg/kg to 100mg/kg, resulting in a daily administration of about 1 mg to 5 grams of compound for a 70kg mammal.

30 The daily topical dosage regimen will be similar to parenteral of .5mg to 100mg/kg and typically be in the range of 10mg to 100mg of compound. For administration to the eyes, .1 to 1mg of compound per administration.

It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically
35 acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e.,

the number of doses of a compound of formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

5 The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

BIOLOGICAL EXAMPLES

10 The collagenase inhibitory activity of compounds of the present invention are determined by the *in vitro* assays as described by the procedure of Cawston and Barrett, Anal. Biochem. 99, 340-345 (1979), and as described in US patent 5,240,598 or 4,599,361 whose disclosures are hereby incorporated by reference. The compound of Example 1 was found to be an effective inhibitor of collagenase activity.


15 The stromelysin inhibitory activity of the compounds of Formula (I) may be determined by the procedure of Cawston et al., Biochem. J., 195, 159-165 (1981), whose disclosure is hereby incorporated by reference.

20 Additional testing for anti-inflammatory and chondroprotective effects of the compounds of Formula (I) may also be done using the adjuvant arthritis (AA) rat model which is well known to those of skill in the art.

25 The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

What is claimed is:

1. A compound according to the formula



5

wherein

R₁ is hydrogen, hydroxy, optionally substituted C₁-6 alkyl, optionally substituted C₁-6 alkenyl, phenyl, optionally substituted phenyl C₁-6 alkyl-, R₇-S(O)_n C₁-6 alkyl-; n is 0 or an integer having a value of 1 or 2;

10 R₇ is C₁-6 alkyl, phenyl, phenyl C₁-6 alkyl, heterocyclic, heterocyclic C₁-6 alkyl, heteroaryl, heteroaryl C₁-6 alkyl, C₁-6 alkyl carbonyl, or phenacyl, all of which may be optionally substituted one to four times independently from C₁-6 alkyl, C₁-6 alkoxy, hydroxy, thio C₁-6 alkyl, amino, halogen, CF₃ or nitro;

R₂ is hydrogen, C₁-6 alkyl, C₁-6 alkenyl, phenyl C₁-6 alkyl, cycloalkyl C₁-6 alkyl, or
15 cycloalkenyl C₁-6 alkyl;

R₃ is hydrogen or methyl;

R₄ is hydrogen, C₁-6 alkyl, cyclopropyl, an amino acid residue, optionally substituted phenyl, optionally substituted phenyl C₁-6 alkyl-, optionally substituted
20 -C₁-6-alkyl-oxy C₁-6 alkyl, optionally substituted -C₁-6 alkyl oxy C₁-6 alkyl phenyl, or an optionally substituted -C₁-6 alkyl oxy phenyl;

wherein the phenyl or benzyl moiety is independently substituted one to four times by halogen, C₁-6 alkyl, C₁-6 alkoxy, hydroxy, thiol, C₁-6 alkylthio-,
-NR₁₂R₁₃, -NHR^a, -NO₂, -C(O)₂R₁₄, -C(O)₂NR₁₂R₁₃, cyanoamino,
R₁₄C(O)-O-, C₁-6 alkyl OH, C₁-6 alkyl-C(O)₂R₁₄, C₁-6 alkyl-oxy-C₁-6 alkyl,
25 C(O)C₁-6 alkylNR₁₂R₁₃, or C₁-6 alkyl-(O)₂C-R₁₄;

R^a is hydrogen, C₁-6 alkyl, or the side chain of an amino acid,

R₁₄ is hydrogen, C₁-6 alkyl, C₃-7 cycloalkyl, C₃-7 cycloalkyl C₁-6 alkyl, arylC₁-6 alkyl, heteroarylC₁-6 alkyl, or heterocyclic C₁-6 alkyl;

R₅ is hydrogen or C₁-6 alkyl;

30 R₆ and R₇ are independently hydrogen, halogen, CF₃, C₁-6 alkyl, aryl, arylC₁-6 alkyl, heteroaryl, heteroarylC₁-6 alkyl, heterocyclic, heterocyclic C₁-6 alkyl, (CHR₈)_m OH, (CHR₈)_m C(O)₂R₁₀, (CHR₈)_m C(OH)(R₉)₂, (CR₈R₉)-OH, C(O)R₁₁,

SUBSTITUTE SHEET (RULE 26)

$C(O)NR_{12}R_{13}$, $C(O)_2R_{10}$, or NO_2 ; or R_6 and R_7 can together form a fused C 2-4 alkylene, aryl or heteroaryl moiety;

m is 0 or an integer having a value of 1 or 2;

m' is an integer having a value of 1, 2, or 3;

R_8 and R_9 are independently hydrogen, C₁₋₄ alkyl or phenyl;

R_{10} is hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₆ alkyl, C₅₋₇ cycloalkenyl, arylC₁₋₆alkyl, heteroarylC₁₋₆alkyl, heterocyclic, heterocyclic C₁₋₆ alkyl all of which may be optionally substituted by halogen, hydroxyl, -C₁₋₆alkoxy, -thioC₁₋₆ alkyl, or CF₃;

R_{11} is hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₆ alkyl, C₅₋₇ cycloalkenyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroarylC₁₋₆alkyl, heterocyclic, heterocyclic C₁₋₆ alkyl all of which may be optionally substituted by halogen, hydroxyl, -C₁₋₆ alkoxy, -thioC₁₋₆ alkyl, or CF₃;

R_{12} and R_{13} are independently hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₆ alkyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroarylC₁₋₆alkyl, heterocyclic, heterocyclic C₁₋₆ alkyl or R_{12} and R_{13} may together with the nitrogen to which they are attached form a 5 to 7 membered ring which may additionally contain another heteroatom selected from O/N/ or S; or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 wherein R_1 is hydrogen or hydroxy.
3. The compound according to Claim 1 wherein R_2 is C₁₋₆ alkyl.
4. The compound according to Claim 1 wherein R_3 is hydrogen.
5. The compound according to Claim 1 wherein R_4 is hydrogen, C₁₋₆ alkyl, cyclopropyl, an amino acid residue, optionally substituted phenyl, optionally substituted phenyl C₁₋₆ alkyl-, optionally substituted(phenyl) -C₁₋₆-alkyl-oxy C₁₋₆alkyl, optionally substituted -C₁₋₆ alkyl oxyC₁₋₆ alkyl phenyl, or an optionally substituted -C₁₋₆ alkyl oxy phenyl;
 wherein the phenyl or benzyl moiety is independently substituted one to four times by halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, thiol, C₁₋₆alkylthio-, -NR₁₂R₁₃, -NHR^a, -NO₂, -C(O)₂R₁₄, -C(O)₂NR₁₂R₁₃, cyanoamino, R₁₄C(O)-O-, C₁₋₆ alkyl OH, C₁₋₆alkyl-C(O)₂R₁₄, C₁₋₆alkyl-oxy-C₁₋₆alkyl, C(O)C₁₋₆ alkylNR₁₂R₁₃, or C₁₋₆alkyl-(O)₂C-R₁₄.

6. The compound according to Claim 1 wherein R₆ and R₇ are independently hydrogen, bromine, chlorine, CF₃, C₁₋₆ alkyl, phenyl, (CHR₈)_m OH, (CHR₈)_m C(O)₂R₁₀, (CHR₈)_m C(OH)(R₉)₂, (CR₈R₉)-OH, C(O)R₁₁, C(O)NR₁₂R₁₃, C(O)₂R₁₀, or NO₂; or R₆ and R₇ can together form a fused C 2-4 alkylene, aryl or heteroaryl moiety;
R₁₀ is hydrogen, or C₁₋₆ alkyl; and
R₁₁ is hydrogen, C₁₋₆ alkyl, or phenyl.
7. The compound according to Claim 6 wherein R₆ and R₇ together form a fused aryl ring.
8. The compound according to Claim 6 wherein R₁ is hydrogen or hydroxy; R₂ is C₁₋₆ alkyl and R₃ is hydrogen.
9. The compound according to Claim 1 wherein one of R₆ and R₇ are hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, phenyl, benzyl, CF₃, bromine, C(O)₂CH₃, C(O)H, CH₂OH, CH(OH)CH₃, CH(OH)isopropyl, CH(OH)phenyl, NO₂, C(O)NH₂, (CH₂)₂C(O)₂CH₃, or both of R₆ and R₇ are methyl, dibromo or together form a fused aryl ring with the imidazole.
10. The compound according to Claim 1 wherein R₄ is hydrogen, methyl, t-butyl, ethyl, propyl, isobutyl, cyclopropyl or benzyl.
11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound according to Claim 1.
12. A method of treating a matrix degrading metalloproteinase mediated disease in an animal in need thereof which method comprises administering to said animal an effective matrix degrading metalloproteinase amount of a compound according to Claim 1.
13. The method according to Claim 12 wherein the matrix degrading metalloproteinase is collagenase.
14. The method according to Claim 12 wherein the matrix degrading metalloproteinase mediated disease is arthritis, osteoporosis, or a bone reabsorption disease.

15. A method of treating inflammation in an animal in need thereof which method comprises administering to said animal an effective amount of a compound according to Claim 1.
16. A method of treating arthritis in an animal in need thereof which method comprises administering to said animal an effective amount of a compound according to Claim 1.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02606

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 233/64, 235/14; A61K 31/415.

US CL :548/304.4, 324.1, 327.1, 338.1, 338.5; 514/394, 398, 400.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/304.4, 324.1, 327.1, 338.1, 338.5; 514/394, 398, 400.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US,A, 5,304,604 [DAVIDSON ET AL.] 19 APRIL 1994, column 3, line 55 through column 4, line 24.	1-15
A	US,A, 4,996,358 [HANDA ET AL.] 26 FEBRUARY 1991, column 1, line 9 through column 2, line 22.	1-15
A	US,A, 5,240,958 [CAMPION ET AL.] 31 AUGUST 1993, column 4, lines 5 through 46.	1-15
A,P	US,A, 5,300,674 [CRIMMIN ET AL.] 05 APRIL 1994, column 1, line 29 through column 2, line 24.	1-15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &* document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 MAY 1995

Date of mailing of the international search report

19 JUN 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MATTHEW V. GRUMBLING

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

THIS PAGE BLANK (USPTO)